Design of hybrid protein-coated magnetic core-mesoporous silica shell nanocomposites for MRI and drug release assessed in a 3D tumor cell model.

Date publication

janvier 2019

Journal

Nanotechnology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BEGIN-COLIN Sylvie , Dr MERTZ Damien , Dr RABINEAU Morgane

Tous les auteurs :
Ménard M, Meyer F, Affolter-Zbaraszczuk C, Rabineau M, Adam A, Duenas-Ramirez P, Begin-Colin S, Mertz D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30641488

Résumé

In this work, we describe the design and the use of a novel theranostic hybrid nanocomposite made of an iron oxide core and a mesoporous silica shell (IO@MS) of ca. 30 nm coated by human serum albumin (HSA) layer for magnetic resonance imaging (MRI) and drug delivery applications. The porosity of IO@MS nanoparticles was loaded with an antitumoral drug, Doxorubicin (Dox) reaching a high drug loading capacity (DLC) of 34w%. To entrap the drug, a tight HSA coating held via isobutyramide (IBAM) binders was deposited. We show that this protein nanoassembly entraps the drugs efficiently and behaves as an innovative enzyme-sensitive gatekeeper that is degraded upon protease action. Finally we assess the Dox release in a 3D cell model via confocal imaging and its cytotoxicity is shown by growth inhibition studies on liver cancer cell spheroids.

Référence

Nanotechnology. 2019 Jan 14;: